Journal Article – Phenotype-Guided Antiobesity Medication Selection Enhances Weight Loss
This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified individuals with obesity into four main phenotypes: “hungry brain” (abnormal satiation), “emotional hunger” (hedonic eating), “hungry gut” (abnormal satiety), and “slow burn” (decreased metabolic rate). A clinical trial showed that the phenotype-guided approach resulted in significantly greater weight loss and […]
Journal Article – Tirzepatide Versus Semaglutide for Obesity Treatment
This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body weight and waist circumference. While both medications led to similar rates of overall adverse events, predominantly gastrointestinal, tirzepatide resulted […]
Journal Article – Implantable Drug Delivery Systems for GLP-1s Receptor Agonists. No more shots! What could go wrong?
Several companies and research groups are actively exploring implantable drug delivery systems for GLP-1 receptor agonists (GLP-1 RAs), aiming to improve patient adherence, convenience, and therapeutic outcomes. Here’s a summary of key players and motivations: Getting drugs into a human body is harder than it looks. The GLP1 need to be in the blood to […]
Journal Article – Real-world use of tirzepatide among individuals without evidence of type2 diabetes: Results from the Veradign® database
March 14, 2025 Hunter Gibble T, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, Liao B, Hankosky ER. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database. Diabetes Obes Metab. 2025 Jun;27(6):3185-3194. doi: 10.1111/dom.16330. Epub 2025 Mar 14. PMID: 40084533; PMCID: PMC12046461. This source describes […]
Journal Article – GIPR Antagonism and GLP-1R Agonism Metabolic Effects
Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros JD, Knerr PJ, Finan B, DiMarchi RD, Sloop KW, Samms RJ, Theis FJ, Tschöp MH, Müller TD. GIPR agonism and antagonism decrease body weight […]
Journal Article – GLP1-RAs and Thyroid Cancer Risk
January 16, 2025Thyroid Vol 35, No. 1 This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2 diabetes, and the risk of developing thyroid cancer. Conducted as a large, international study across multiple sites in six countries, it compared GLP1-RA users with those using dipeptidyl peptidase-4 inhibitors (DPP-4is), another class […]
Draft FDA Guidance – Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction – Guidance for Industry
Released: January 7, 2025Level 1 GuidanceDraft This draft guidance document from the U.S. Food and Drug Administration (FDA) outlines recommendations for the development of drugs and biological products intended for weight reduction and maintenance in both adult and pediatric patients with obesity or overweight and related comorbidities. It provides information on clinical trial design, including subject populations, trial size and duration, and the assessment […]
Review Article – GLP-1-Based Therapies for Diabetes, Obesity and Beyond
by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8. Epub ahead of print. PMID: 40281304. This review article discusses GLP-1-based therapies, highlighting their effectiveness for managing type 2 diabetes and obesity, including well-known drugs like semaglutide and tirzepatide. The text details the evolution […]
News Article – WHO Leaning Toward Adding Obesity Drugs for Adults to Essential Medicines List: Reuters
May 2, 2025 According to the provided text from Fox News, the World Health Organization (WHO) is planning to endorse the use of GLP-1 weight-loss medications for adults as a strategy to combat the global obesity crisis. This support aims to improve access to these drugs, particularly in low- and middle-income countries, where a significant portion of the world’s obese population resides. The […]
Healthcare News – Cigna doubles down on GLP-1 support programs with 2 new launches
The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article focuses on Cigna’s strategies regarding the growing demand for GLP-1 weight loss medications. Cigna’s health services division, Evernorth, is launching two new support programs aimed at assisting patients and easing concerns for payers regarding the high […]